Tuesday, 29 September 2026Updated 28m ago
← Top stories
Market move● Neutral for Indian equities

178% Intraday Surge: This US Biopharma Stock Skyrockets After Eye Disease Drug Clears Key Hurdle

1 source · first seen 23:18 28 Sept · updated 23:18 28 Sept

The brief

Written from 1 report · check the source before you trade
  • Kodiak completed five successful Phase 3 trials
  • The company says it can submit the treatments for US FDA approval later

Tags on this story

Pick a tag to see all its stories
Pharma and healthcare35 todayWall Street39 today

Linked by the tag Pharma and healthcare

85 stories this week
  1. 28 SeptUS exempts India and 19 nations from 100% tariff on certain speciality drugs: ReportPolicy · 1 source · US exempts certain speciality drugs and ingredients imported from India from tariffs
  2. 27 SeptFortis says independent audit will establish non-involvement in Singh brothers’ share transfersLegal · 2 sources · Supreme Court cleared the way for an independent forensic audit of the share transfers
  3. 27 SeptFortis confident of clean chit from audit in Singh brothers’ disputeLegal · 1 source · Fortis expects a clean chit from the audit in the Singh brothers’ dispute
  4. 25 SeptSupreme Court allows independent forensic audit of Fortis transactions in Daiichi disputeLegal · 7 sources · The Supreme Court declined to interfere with Delhi High Court orders allowing the audit
  5. 25 SeptRegulator mulls digital platform for drugmakers' test reportsPolicy · 1 source · India’s drug regulator is developing a digital platform for consumers to view batch-level quality-test reports
All Pharma and healthcare stories →

Read the reports

1 report · earliest 23:18
NDTV Profit178% Intraday Surge: This US Biopharma Stock Skyrockets After Eye Disease Drug Clears Key Hurdle23:18